CONTEXT: Peer reviewed article on RWE in multiple myeloma | Pre-publication preview
IMPACT: Medium
READ TIME: 1 min
Quality Level Mean [1 – 10]: 4
1. “We evaluated clinical outcomes among RRMM patients in the 1-year following treatment with pomalidomide or daratumumab and compared economic outcomes between RRMM patients and non-MM patients.”
2. “RRMM patients were also matched to a non-MM comparator cohort and economic outcomes were compared between the two cohorts.”
3. “Adjusting for baseline characteristics, patients with RRMM had 4.9 times (95% CI 3.8-6.4, P < .0001) the total healthcare costs compared with patients without MM.”
4. “The major driver of total costs among RRMM patients was pharmacy costs (67.3%).”
5. “CONCLUSION: RRMM patients showed a high frequency of AEs, low OS, and a substantial economic burden suggesting need for effective treatment options.”